ArticleTargeted oncology2024
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Taizo Uchimoto et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
7 papers cite it
this papercites it